Saturday, August 29, 2015 1:21:04 PM
Please keep comments to the company facts and development such as the hiring of full time scientists in Jan-Feb, multiple abstracts as well as oral presentations accepted at international scientific gatherings (did not happen before on any scale near 2015), new scientific board members who are specialists in the areas of RGBP product development, one new board member who is a head at one of the few nationally recognized Cancer Centers now working with RGBP to develop dCellVax for glioma as well as providing testing and data for general dCellVax IND approval, CRL (GLP) entity providing all the testing for the data to be submitted for HemaX IND approval to be completed within next 2 weeks (never happened before in company history to have such level of outside, independent lab expertise to move product line forward), several new patents and other IP purchased or filed in 2015.
I may have missed a few points, but hopefully those new to RGBP (following company less than one year) can get the idea from the facts that this is not "the same 'ol company" we've followed in the past.
I may have missed a few points, but hopefully those new to RGBP (following company less than one year) can get the idea from the facts that this is not "the same 'ol company" we've followed in the past.
Recent RGBP News
- Regen BioPharma Update on Orphan Drug Application for HemaXellerate Will Be Presented At Emerging Growth Conference on September 24, 2025 • GlobeNewswire Inc. • 09/23/2025 12:00:00 PM
- Regen BioPharma Prepares Response For FDA Regarding Its Orphan Drug Application for HemaXellerate • GlobeNewswire Inc. • 09/16/2025 12:00:00 PM
